Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

Completed · Phase 3

Conditions studied: Prostate Cancer

In brief

RATIONALE: Antiandrogen withdrawal may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of ketoconazole and hydrocortisone for antiandrogen withdrawal in treating men with prostate cancer that is refractory to hormone therapy.

Key facts

Study ID

NCT00002760

Run by

Alliance for Clinical Trials in Oncology

People needed

260

Starts

1996-08-01

Expected to finish

2009-04-01

Last updated by the study team

2016-06-28

Who can join

Age: any, up to 120. Sex: male. Healthy volunteers: not accepted.

Where it is running

• UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
• University of Minnesota Cancer Center — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.